A detailed history of Wellington Management Group LLP transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 221,562 shares of AVIR stock, worth $720,076. This represents 0.0% of its overall portfolio holdings.

Number of Shares
221,562
Previous 255,166 13.17%
Holding current value
$720,076
Previous $844,000 12.09%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.17 - $4.02 $106,524 - $135,088
-33,604 Reduced 13.17%
221,562 $742,000
Q2 2024

Aug 13, 2024

SELL
$3.31 - $4.04 $313,913 - $383,145
-94,838 Reduced 27.1%
255,166 $844,000
Q1 2024

May 15, 2024

BUY
$3.09 - $4.56 $1.08 Million - $1.6 Million
350,004 New
350,004 $1.41 Million
Q1 2023

May 12, 2023

SELL
$3.0 - $4.97 $34,521 - $57,189
-11,507 Reduced 3.86%
286,233 $958,000
Q4 2022

Feb 13, 2023

BUY
$4.35 - $6.17 $303,521 - $430,511
69,775 Added 30.61%
297,740 $1.43 Million
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $767,249 - $1.23 Million
139,754 Added 158.43%
227,965 $1.3 Million
Q2 2022

Aug 15, 2022

SELL
$5.33 - $8.18 $692 - $1,063
-130 Reduced 0.15%
88,211 $626,000
Q1 2022

May 16, 2022

BUY
$5.5 - $9.19 $94,792 - $158,389
17,235 Added 24.24%
88,341 $637,000
Q4 2021

Feb 11, 2022

BUY
$7.67 - $44.59 $388,991 - $2.26 Million
50,716 Added 248.73%
71,106 $635,000
Q3 2021

Nov 15, 2021

SELL
$21.33 - $35.06 $10 Million - $16.4 Million
-468,955 Reduced 95.83%
20,390 $715,000
Q2 2021

Aug 16, 2021

BUY
$19.22 - $59.08 $8.59 Million - $26.4 Million
446,979 Added 1055.04%
489,345 $10.5 Million
Q1 2021

May 17, 2021

SELL
$41.42 - $88.44 $14,455 - $30,865
-349 Reduced 0.82%
42,366 $2.62 Million
Q4 2020

Feb 12, 2021

BUY
$26.36 - $41.78 $1.13 Million - $1.78 Million
42,715 New
42,715 $1.78 Million

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $271M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.